Cardiovascular Systems, Inc.(CSI) is a medical device company focused on developing and commercializing minimally invasive treatment solutions for vascular disease. The Company’s primary product, the Diamondback 360 PAD System, is a catheter-based platform capable of treating a range of plaque types in leg arteries both above and below the knee. In August 2007, the United States Food and Drug Administration (FDA) granted the Company 510(k) clearance for use of the Diamondback 360 as a therapy for treatment of patients with peripheral artery disease (PAD). As of June 30, 2009, it was selling the Diamondback 360 in 556 accounts that had completed an estimated 15,000 procedures. On February 25, 2009, Replidyne, Inc. completed its merger with Cardiovascular Systems, Inc. Pursuant to the merger, Replidyne merged with and into Cardiovascular Systems, Inc., with Cardiovascular Systems, Inc. continuing after the merger as the surviving company and a wholly owned subsidiary of Replidyne.